Drug intelligence / Profile preview

USP703

Development stage: Preclinical
Lead developer: Uscare Pharm

Overview

USP703 is an investigational therapeutic candidate currently in the discovery stage, developed by Uscare Pharm. It is being evaluated for mucosal protection, an indication aimed at preserving the integrity of mucous membranes against damage from various agents or conditions. The asset is categorized within Uscare Pharm's "Product Innovation" pipeline, which distinguishes it from their "Material Innovation" and "Platform Innovation" categories. As of current reporting, specific details regarding its molecular modality, target, and mechanism of action have not been publicly disclosed.

Beyond the preview

Go deeper on USP703.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on USP703.

Explore the full profile